New hope for tough lung cancer: drug MGC018 under trial
NCT ID NCT06227546
First seen Apr 23, 2026 · Last updated Jun 18, 2026 · Updated 10 times
Summary
This study tests a drug called MGC018 in people with extensive-stage small-cell lung cancer that has come back or not responded to treatment. The main goal is to see if the drug can shrink tumors in at least 25% of participants. Patients receive the drug through an IV every 28 days, with regular scans and blood tests to monitor effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.